Hope for lupus kidney patients: new drug shows promise in Long-Term trial
NCT ID NCT06711887
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This 2-year study looks at how well the drug ianalumab works for adults with lupus nephritis, a kidney disease caused by lupus. Some participants who already responded to treatment will stop the drug to see if they stay well, while others will continue or start open-label ianalumab. The goal is to check safety and whether the drug can keep kidney flares away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGSalvador, Estado de Bahia, 40150 150, Brazil
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGShantou, Guangdong, 515000, China
-
Novartis Investigative Site
RECRUITINGLiuzhou, Guangxi, 545005, China
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430060, China
-
Novartis Investigative Site
RECRUITINGBinzhou, Shandong, 256603, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, 510080, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, 510280, China
-
Novartis Investigative Site
RECRUITINGShanghai, 200080, China
-
Novartis Investigative Site
RECRUITINGBarranquilla, Atlántico, 080020, Colombia
-
Novartis Investigative Site
RECRUITINGBudapest, H-1097, Hungary
-
Novartis Investigative Site
RECRUITINGLeón, Guanajuato, 37160, Mexico
-
Novartis Investigative Site
RECRUITINGOaxaca City, 68020, Mexico
-
Novartis Investigative Site
RECRUITINGQuerétaro, 76070, Mexico
-
Novartis Investigative Site
RECRUITINGBucharest, 022328, Romania
-
Novartis Investigative Site
RECRUITINGSingapore, 169608, Singapore
-
Novartis Investigative Site
RECRUITINGSingapore, S308433, Singapore
-
Novartis Investigative Site
RECRUITINGSuwon, Gyeonggi-do, 16499, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 04763, South Korea
-
Novartis Investigative Site
RECRUITINGTaichung, 40447, Taiwan
-
Novartis Investigative Site
RECRUITINGSongkhla, Hat Yai, 90110, Thailand
-
Novartis Investigative Site
RECRUITINGBangkok, 10330, Thailand
-
Novartis Investigative Site
RECRUITINGBangkok, 10400, Thailand
-
Novartis Investigative Site
RECRUITINGChiang Mai, 50200, Thailand
Conditions
Explore the condition pages connected to this study.